恒瑞医药(600276.SH)：注射用SHR-9839(sc)等多款药物临床试验获批

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for multiple clinical trial applications, indicating a significant advancement in its drug development pipeline [1] Group 1: Clinical Trials - The company and its subsidiaries have been granted approval for clinical trials of several injectable drugs, including SHR-9839(sc), SHR-A2009, SHR-1826, HRS-4642, and others [1] - A specific trial will focus on the safety, tolerability, and efficacy of SHR-9839(sc) in combination with anti-tumor drugs in solid tumor subjects, categorized as an IB/II phase study [1]